孟鲁司特钠对COPD急性发作患者肺功能及炎性介质的影响

Effects of montelukast sodium on pulmonary function and inflammatory factors of patients with acute exacerbation of chronic obstructive pulmonary disease

目的研究布地奈德与孟鲁司特钠联用对慢性阻塞性肺疾病(COPD)急性发作患者肺功能及炎性介质的影响。方法将132例COPD急性发作患者随机分入两组,每组66例。对照组雾化吸入布地奈德混悬液,2 mg/次,2次/d;治疗组在此基础上加用孟鲁司特钠,每晚睡前口服10 mg。所有患者均持续治疗2 w。比较两组治疗前及治疗后肺功能、炎性介质的变化。结果治疗后,治疗组血清IL-6、IL-8、TNF-α表达水平显著低于对照组(P<0.05),且肺功能指标FEV1、FEV1/FVC较自身治疗前也有显著增加(P<0.05),并明显高于对照组治疗后水平(P<0.05)。结论布地奈德与孟鲁司特钠联用治疗COPD急性发作、抗炎及改善肺功能的效果优于单独使用布地奈德。

Objective To study the effects of montelukast sodium combined with budesonide on the pulmonary function and inflammatory factors of patients with acute exacerbation of chronic obstructive pulmonary disease（COPD）. Methods 132 patients with acute exacerbation of COPD were randomly divided into two groups with 66 ones in each group. The control group received inhalation with budesonide 2 mg every time and twice per day. Based on the same treatment as the control group, the treatment group orally took montelukast sodium 10 mg/d, pohs. The courses of treatment were 2 weeks. Comparison was made in the changes of pulmonary function and inflammatory factors before and after the treatment between the two groups. Results After the treatment, the expression levels of serum IL-6, IL-8, and TNF-α in the treatment group were significantly lower than those in the control group（P 〈0.05）. FEV1 and FEV1/FVC in the treatment group significantly increased after the treatment compared with those before the treatment（ P 〈0.05）and higher than those in the control group after the treatment（P 〈0.05）. Conclusion Budesonide plus montelukast sodium for the treatment of COPD acute exacerbation have better results in anti-inflammatory effect and improvement in pulmonary function than the treatment simply with budesonide.